PTC Therapeutics预计26财年产品收入在7亿至8亿美元之间

2026-01-13 00:09

PTC Therapeutics (PTCT) on Monday reported unaudited 2025 product and royalty revenue of ~$823.4 million, exceeding guidance, and unaudited 2025 product revenue of ~$587.8 million.
PTC expects to report ~$235.7 million of full-year 2025 royalty revenue associated with Evrysdi.
It posted unaudited Sephience Q4 2025 net revenue of ~$92.5 million, including $81.6 million in the US and $10.9 million ex-US whereas for 2025 the revenue was ~$112.1 million.
The company said 1,134 patient start forms were received in the US as of December 31, 2025. Additional Sephience launches are expected in 2026, including in Japan, Brazil and other geographies.
Cash, cash equivalents, and marketable securities of ~$1.94 billion as of December 31, 2025.
2026 Financial Guidance For the full year 2026, PTC anticipates:
- Total product revenue of $700 to $800 million, excluding Evrysdi royalty revenue and collaboration revenue.
- GAAP R&D and SG&A expense of $775 to $815 million.
- Non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million.
PTCT is -2.93% to $75.26.
Source: Press Release

More on PTC Therapeutics